Advertisement
Screener

Acumen Pharmaceuticals, Inc. (ABOS) Debt Securities, Available-for-sale, Gain (Loss)

1.8 / 5 stars · 12/33 Roast Me

Acumen Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Gain (Loss)

Acumen Pharmaceuticals, Inc. (ABOS) reported Debt Securities, Available-for-sale, Gain (Loss) of $0 for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.

Financial Statements › Income Statement › Other Income

us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2025-08-12

  • Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2025-06-30 was $0.00.
  • Acumen Pharmaceuticals, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2024-06-30 was $0.00.
Period endDebt Securities, Available-for-sale, Gain (Loss) 3 monthDebt Securities, Available-for-sale, Gain (Loss) 6 month
2025-06-30$0.00
10-Q · filed 2025-08-12
$0.00
10-Q · filed 2025-08-12
2024-06-30$0.00
10-Q · filed 2025-08-12
$0.00
10-Q · filed 2025-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48